News Results
There are 642,548 News Results
Jun 16, 2025
PARIS, June 16, 2025 /PRNewswire/ -- This Sunday, June 15th, 2025, the Franco-German TV channel Arte broadcast the documentary "AI and the Art Market", directed by Frédéric Biamonti, as part...
Jun 17, 2025
SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up; ~75 day half-life demonstrated,...
Jul 14, 2025
-- One-year data from CAHtalyst((TM)) Adult study demonstrated lasting reductions in glucocorticoid dose and improvement in clinical outcomes in adults with classic congenital adrenal hyperplasia -- Results build upon previously...
Jul 14, 2025
-- Adult and pediatric patients with classic congenital adrenal hyperplasia treated with CRENESSITY(®) (crinecerfont) achieved clinically meaningful weight reductions -- Substantial improvements in insulin resistance were also observed in both...
Jul 31, 2025
OAKLAND, Calif., July 31, 2025 /PRNewswire/ -- PG&E Corporation (NYSE: PCG) is on track to deliver solid 2025 financial results. Financial progress includes: -- GAAP earnings were $0.24 per share...
Aug 1, 2025
-- 2025 second quarter GAAP earnings of $0.22 per diluted share -- 2025 second quarter ongoing earnings of $0.25 per diluted share -- Proposed transaction with Blackstone Infrastructure expected to...
Aug 6, 2025
-- Reports second quarter results, including net income of $86 million, Adjusted EBITDA((1)), excluding one-time transaction-related expenses((2)), of $464 million and Distributable Cash Flow, as adjusted((1)), of $300 million --...
Aug 7, 2025
REHOVOT, Israel , Aug. 7, 2025 /PRNewswire/ -- Nova (Nasdaq: NVMI) today announced financial results for the second quarter, the three-month period ended June 30, 2025. https://mma.prnewswire.com/media/1446151/Nova_Logo.jpg Second Quarter 2025...
Aug 7, 2025
Dosed the First Patient in the 8-Week 48 mg MAD Cohort of its Phase 1 Clinical Trial to Further Explore Maximum Tolerated Dose of DA-1726 for the Treatment of Obesity;...
